EHA 2022 | Safety & efficacy of isatuximab plus pomalidomide & dexamethasone in elderly patients with R/R MM

This is from the ICARIA trial, which led to the approval of isatuximab pom-dex. So first, the PFS benefit was very good for the total population. We have seen the overall survival data on total population, which it’s [inaudible 00:00:21] significant, but it’s very, very close. Then we have looked at both the frail and the fit and as we’re referring to how this performs in the elderly versus the young and we see that the efficacy regarding PFS and OS is at least as good in the elderly group as it is in the younger group. So I think this speaks for the very good safety of this combination of the CD38 antibody and PD. And this is a really good regimen for the elderly. I think the only sort of pitfall or caveat for this combination is that, this is a third line regimen. So if a patient receives daratumumab in second line in DRd or DKd or DPd, they are maybe not expected to respond as well to this regimen. So this is mainly for the patients who have not received the CD38 antibody from before.

But now that dara is sort of coming into first line and they will get the second line without the CD38 antibody. I think to re-expose in third line with this known efficacy on safety, I think that’s still a very good option for the patients in third line after a non-CD38 line in second line, which will be more common now that the dara-Rd is moving into first line.